398 related articles for article (PubMed ID: 26800081)
41. Efficient in vitro amplification of a mouse-adapted scrapie prion protein.
Murayama Y; Yoshioka M; Yokoyama T; Iwamaru Y; Imamura M; Masujin K; Yoshiba S; Mohri S
Neurosci Lett; 2007 Feb; 413(3):270-3. PubMed ID: 17174030
[TBL] [Abstract][Full Text] [Related]
42. Investigations of a prion infectivity assay to evaluate methods of decontamination.
Fichet G; Comoy E; Dehen C; Challier L; Antloga K; Deslys JP; McDonnell G
J Microbiol Methods; 2007 Sep; 70(3):511-8. PubMed ID: 17640752
[TBL] [Abstract][Full Text] [Related]
43. Sensitive protein misfolding cyclic amplification of sporadic Creutzfeldt-Jakob disease prions is strongly seed and substrate dependent.
Bélondrade M; Nicot S; Mayran C; Bruyere-Ostells L; Almela F; Di Bari MA; Levavasseur E; Watts JC; Fournier-Wirth C; Lehmann S; Haïk S; Nonno R; Bougard D
Sci Rep; 2021 Feb; 11(1):4058. PubMed ID: 33603091
[TBL] [Abstract][Full Text] [Related]
44. A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay.
Edgeworth JA; Sicilia A; Linehan J; Brandner S; Jackson GS; Collinge J
J Gen Virol; 2011 Mar; 92(Pt 3):718-26. PubMed ID: 21084494
[TBL] [Abstract][Full Text] [Related]
45. White blood cell-based detection of asymptomatic scrapie infection by ex vivo assays.
Halliez S; Jaumain E; Huor A; Douet JY; Lugan S; Cassard H; Lacroux C; Béringue V; Andréoletti O; Vilette D
PLoS One; 2014; 9(8):e104287. PubMed ID: 25122456
[TBL] [Abstract][Full Text] [Related]
46. Evaluation of the protection of primates transfused with variant Creutzfeldt-Jakob disease-infected blood products filtered with prion removal devices: a 5-year update.
Lescoutra-Etchegaray N; Jaffré N; Sumian C; Durand V; Correia E; Mikol J; Luccantoni-Freire S; Culeux A; Deslys JP; Comoy EE
Transfusion; 2015 Jun; 55(6):1231-41. PubMed ID: 25647476
[TBL] [Abstract][Full Text] [Related]
47. Application of PMCA to screen for prion infection in a human cell line used to produce biological therapeutics.
Lyon A; Mays CE; Borriello F; Telling GC; Soto C; Pritzkow S
Sci Rep; 2019 Mar; 9(1):4847. PubMed ID: 30890734
[TBL] [Abstract][Full Text] [Related]
48. CJD: update for dental staff.
Scully C; Smith AJ; Bagg J
Dent Update; 2006 Oct; 33(8):454-6, 458-60. PubMed ID: 17087448
[TBL] [Abstract][Full Text] [Related]
49. Homogenous photocatalytic decontamination of prion infected stainless steel and titanium surfaces.
Berberidou C; Xanthopoulos K; Paspaltsis I; Lourbopoulos A; Polyzoidou E; Sklaviadis T; Poulios I
Prion; 2013; 7(6):488-95. PubMed ID: 24247293
[TBL] [Abstract][Full Text] [Related]
50. Decontamination of surgical instruments from prions. II. In vivo findings with a model system for testing the removal of scrapie infectivity from steel surfaces.
Lemmer K; Mielke M; Kratzel C; Joncic M; Oezel M; Pauli G; Beekes M
J Gen Virol; 2008 Jan; 89(Pt 1):348-358. PubMed ID: 18089760
[TBL] [Abstract][Full Text] [Related]
51. PrPTSE distribution in a primate model of variant, sporadic, and iatrogenic Creutzfeldt-Jakob disease.
Herzog C; Rivière J; Lescoutra-Etchegaray N; Charbonnier A; Leblanc V; Salès N; Deslys JP; Lasmézas CI
J Virol; 2005 Nov; 79(22):14339-45. PubMed ID: 16254368
[TBL] [Abstract][Full Text] [Related]
52. Development of a sensitive real-time quaking-induced conversion (RT-QuIC) assay for application in prion-infected blood.
Thomas CM; Salamat MKF; de Wolf C; McCutcheon S; Blanco ARA; Manson JC; Hunter N; Houston EF
PLoS One; 2023; 18(11):e0293845. PubMed ID: 37917783
[TBL] [Abstract][Full Text] [Related]
53. Prions in the urine of patients with variant Creutzfeldt-Jakob disease.
Moda F; Gambetti P; Notari S; Concha-Marambio L; Catania M; Park KW; Maderna E; Suardi S; Haïk S; Brandel JP; Ironside J; Knight R; Tagliavini F; Soto C
N Engl J Med; 2014 Aug; 371(6):530-9. PubMed ID: 25099577
[TBL] [Abstract][Full Text] [Related]
54. Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrP) associated with variant Creutzfeldt-Jakob disease.
Jones M; Peden AH; Yull H; Wight D; Bishop MT; Prowse CV; Turner ML; Ironside JW; MacGregor IR; Head MW
Transfusion; 2009 Feb; 49(2):376-84. PubMed ID: 18980616
[TBL] [Abstract][Full Text] [Related]
55. Prominent and persistent extraneural infection in human PrP transgenic mice infected with variant CJD.
Béringue V; Le Dur A; Tixador P; Reine F; Lepourry L; Perret-Liaudet A; Haïk S; Vilotte JL; Fontés M; Laude H
PLoS One; 2008 Jan; 3(1):e1419. PubMed ID: 18183299
[TBL] [Abstract][Full Text] [Related]
56. Prevalence of detectable abnormal prion protein in persons incubating vCJD: plausible incubation periods and cautious inference.
Cooper JD; Bird SM; de Angelis D
J Epidemiol Biostat; 2000; 5(4):209-19. PubMed ID: 11055271
[TBL] [Abstract][Full Text] [Related]
57. Implications for Creutzfeldt-Jakob disease (CJD) in dentistry: a review of current knowledge.
Walker JT; Dickinson J; Sutton JM; Marsh PD; Raven ND
J Dent Res; 2008 Jun; 87(6):511-9. PubMed ID: 18502958
[TBL] [Abstract][Full Text] [Related]
58. Constant transmission properties of variant Creutzfeldt-Jakob disease in 5 countries.
Diack AB; Ritchie D; Bishop M; Pinion V; Brandel JP; Haik S; Tagliavini F; Van Duijn C; Belay ED; Gambetti P; Schonberger LB; Piccardo P; Will RG; Manson JC
Emerg Infect Dis; 2012 Oct; 18(10):1574-9. PubMed ID: 23017202
[TBL] [Abstract][Full Text] [Related]
59. Diagnosing Sporadic Creutzfeldt-Jakob Disease by the Detection of Abnormal Prion Protein in Patient Urine.
Luk C; Jones S; Thomas C; Fox NC; Mok TH; Mead S; Collinge J; Jackson GS
JAMA Neurol; 2016 Dec; 73(12):1454-1460. PubMed ID: 27699415
[TBL] [Abstract][Full Text] [Related]
60. Improving the Predictive Value of Prion Inactivation Validation Methods to Minimize the Risks of Iatrogenic Transmission With Medical Instruments.
Moudjou M; Castille J; Passet B; Herzog L; Reine F; Vilotte JL; Rezaei H; Béringue V; Igel-Egalon A
Front Bioeng Biotechnol; 2020; 8():591024. PubMed ID: 33335894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
